Skip to content

The Effect of Dexmedetomidine for Suprascapular Nerve Block With Axillary Nerve Block

The Effect of Dexmedetomidine for Suprascapular Nerve Block With Axillary Nerve Block on Plasma Cortisol and Pain-related Cytokines After Arthroscopic Rotator Cuff Repair: a Randomized Controlled Trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04398589
Enrollment
46
Registered
2020-05-21
Start date
2015-05-20
Completion date
2016-06-30
Last updated
2020-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthroscopic Rotator Cuff Repair, Axillary Nerve Block, Dexmedetomidine, Pain Related Cytokine, Postoperative Pain, Suprascapular Nerve Block

Brief summary

Suprascapular nerve block (SSNB) is most commonly used for relieving postoperative pain of arthroscopic rotator cuff repair and it can be used in combination with axillary nerve block (ANB). Dexmedetomidine (DEX) is known as a type of alpha agonist which can elongate the duration of regional block. The aim of this study was to compare the results of dexmedetomidine combined with SSNB and ANB with SSNB and ANB alone on postoperative pain, satisfaction, and pain-related cytokines within the first 48 hours after arthroscopic rotator cuff repair. Forty patients with rotator cuff tears who had undergone arthroscopic rotator cuff repair were enrolled in this single center, double-blinded randomized controlled trial study. Twenty patients were randomly allocated to group 1 and received ultrasound-guided SSNB and ANB using each mixture of 0.5 ml (50 μg) of DEX and 9.5 ml of 0.75% ropivacaine preemptively. The other 20 patients were allocated to group 2 and underwent ultrasound-guided SSNB and ANB alone using a mixture of 0.5 ml of normal saline and 9.5 ml of ropivacaine. The visual analog scale (VAS) for pain and patient satisfaction (SAT) scores were checked within 48 h postoperatively. The plasma interleukin (IL)-6, -8,-1β, cortisol, and serotonin levels were also measured within 48 h postoperatively.

Interventions

DRUGDexmedetomidine injection

We used 9.5 ml of 0.75% ropivacaine and 0.5 ml (50 μg) of dexmedetomidine each for preemptive suprascapular nerve block and axillary nerve block just before arthroscopic repair of rotator cuff tear.

DRUGSaline injection

We used 9.5 ml of 0.75% ropivacaine and 0.5 ml normal saline each for preemptive suprascapular nerve block and axillary nerve block just before arthroscopic repair of rotator cuff tear.

Sponsors

Hallym University
CollaboratorOTHER
Chuncheon Sacred Heart Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* defined rotator cuff tear on preoperative MRI, which indicated repair * acceptable arthroscopic surgery, including rotator cuff repair * patients \>20 years old * acceptable routine regional blocks and patient-controlled analgesia (PCA)

Exclusion criteria

* did not undergo arthroscopic rotator cuff repair * stopped PCA before 48 h postoperatively due to side effects * had a concomitant operation for a Bankart lesion * had a history of shoulder operation or fracture * had a concomitant neurological disorder around the shoulder * underwent conversion to open surgery from the arthroscopy * had contraindications for the routine regional blocks used in this study * had an known allergy or hypersensitivity against ropivacaine or dexmedetomidine, including other amino-amide local anesthetics or α2-adrenoceptor agonists.

Design outcomes

Primary

MeasureTime frameDescription
visual analog scale of painchange from baseline VAS pain score at hour 48The VAS pain score was based on a scale from 0 to 10, where 0 indicated no pain and 10 indicated severe pain.

Secondary

MeasureTime frameDescription
Plasma cortisol levelchange from baseline plasma cortisol level at hour 48A 3-ml blood sample was retrieved from the peripheral vein of the contralateral upper limb or both lower limbs per sampling.
Plasma IL-6 levelchange from baseline plasma IL-6 level at hour 48A 3-ml blood sample was retrieved from the peripheral vein of the contralateral upper limb or both lower limbs per sampling.
patient's satisfactionchange from baseline patient's satisfaction score at hour 48patient's satisfaction score was based on a scale from 0 to 10, where 0 indicated no satisfaction and 10 indicated much satisfaction.
Plasma IL-1β levelchange from baseline plasma IL-1β level at hour 48A 3-ml blood sample was retrieved from the peripheral vein of the contralateral upper limb or both lower limbs per sampling.
Plasma serotonin levelchange from baseline plasma serotonin level at hour 48A 3-ml blood sample was retrieved from the peripheral vein of the contralateral upper limb or both lower limbs per sampling.
Plasma IL-8 levelchange from baseline plasma IL-8 level at hour 48A 3-ml blood sample was retrieved from the peripheral vein of the contralateral upper limb or both lower limbs per sampling.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026